Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immatics Raises €54 Million Series C To Fund Pivotal Therapeutic Cancer Vaccine Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

One of the largest European fundraisings this year, the round will help advance a potential therapeutic vaccine for kidney cancer through Phase III.

You may also be interested in...



Germany’s Immatics Biotech Raises $46M In Series D To Complete Cancer Vaccine Development

With one of the largest VC-funded financings in Europe this year, the German biotech receives sufficient funds to allow it to prepare marketing submissions for its lead renal cancer vaccine.

New EU-Funded Consortium Aims To Develop Targeted Cancer Vaccines

A clinical trial is expected to start in the U.S. and Europe in 2014 of an individualized approach to developing a cancer vaccine for glioblastoma patients.

Wealthy Families Play A Growing Role in European Biotech Financing

The continued dearth of venture capital in Europe is highlighting the key role played by wealthy families as an alternative – or at least complementary – source of finance for biopharmaceutical firms.

Related Content

Topics

UsernamePublicRestriction

Register

PS071209

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel